Remicade Does Not Cause Arterial Thrombosis and May Actually Reduce Atherosclerotic Risk in Inflammatory Conditions
Remicade (infliximab) does not cause arterial thrombosis or increase atherosclerosis; rather, it is specifically recommended as first-line treatment for arterial involvement in inflammatory vasculitis and may reduce atherosclerotic cardiovascular risk by controlling systemic inflammation. The evidence demonstrates that infliximab treats—rather than causes—arterial thrombosis in appropriate clinical contexts.
Evidence from Guidelines: Infliximab as Treatment for Arterial Disease
The most recent and authoritative evidence comes from the 2025 EULAR guidelines for Behçet's syndrome, which recommend infliximab as first-line treatment specifically for arterial involvement, including arterial aneurysms and thrombosis 1. This represents a major shift from 2018 recommendations, based on:
- An RCT showing infliximab provided higher remission rates compared to cyclophosphamide at week 24 in patients with arterial aneurysms and/or thrombosis 1
- Lower frequency of mild and moderate adverse events with infliximab compared to cyclophosphamide 1
- Retrospective studies demonstrating high remission and low relapse rates with long-term infliximab use for vascular involvement 1
The guidelines explicitly state infliximab should be continued for at least 5 years as maintenance therapy for arterial involvement 1, which would be contraindicated if the drug itself promoted arterial thrombosis.
Cardiovascular Safety Profile from FDA Labeling
The FDA-approved prescribing information for Remicade includes a specific warning about cardiovascular events, but this is limited to worsening heart failure in patients with moderate-to-severe heart failure (NYHA class III/IV) 2. The label specifically contraindicates doses >5 mg/kg in this population 2.
Importantly, the FDA label documents cardiovascular and cerebrovascular reactions (cerebrovascular accidents, myocardial infarctions, arrhythmias) occurring during and within 24 hours of infusion 2, but these are acute infusion-related events, not chronic atherosclerotic disease progression. The label does not list arterial thrombosis or atherosclerosis acceleration as adverse effects 2.
Distinguishing Context: When Infliximab Should NOT Be Used
The 2021 AHA/ASA stroke prevention guidelines provide critical context: infliximab should NOT be used to treat giant cell arteritis 3. A phase II trial showed patients receiving infliximab had higher risk of disease activity and lower chances of remission compared to placebo 3. This is disease-specific and does not indicate infliximab causes arterial thrombosis—rather, it is simply ineffective for this particular vasculitis.
Research Evidence: Mixed but Generally Protective
The research literature presents nuanced findings:
Potentially Protective Effects:
- A 2012 RCT showed infliximab plus methotrexate caused significantly greater reduction in pulse wave velocity (a marker of arterial stiffness) compared to methotrexate alone in early rheumatoid arthritis, suggesting prevention of atherosclerosis progression by improving vascular function 4
- A 2026 review notes that while some RA treatments may aggravate atherogenesis, biologics including infliximab can reduce atherosclerotic risk by modulating inflammatory pathways 5
Concerning Findings:
- One small 2009 study (n=14) reported worsening intima-media thickness in 7 RA patients treated with infliximab over 12 months compared to 7 controls 6
- A 2013 case report described acute renal artery occlusion 3 days after first infliximab infusion for ulcerative colitis, though extensive workup found no other predisposing factors 7
- Laboratory studies show anti-infliximab antibodies can neutralize infliximab's protective effects on coronary endothelial cells stimulated by inflammatory cytokines 8
Clinical Interpretation and Practical Guidance
The weight of evidence, particularly from high-quality guidelines, indicates infliximab does not cause arterial thrombosis or accelerate atherosclerosis. The apparent contradiction in the literature reflects:
Disease-specific effects: Infliximab treats arterial involvement in Behçet's syndrome [1-1] but is ineffective in giant cell arteritis 3
Inflammation vs. drug effect: Uncontrolled systemic inflammation in RA and inflammatory bowel disease independently drives atherosclerosis. Effective anti-inflammatory therapy generally reduces cardiovascular risk, though the 2009 study 6 suggests individual variability
Rare idiosyncratic events: The single case report of renal artery thrombosis 7 likely represents an extremely rare idiosyncratic reaction rather than a class effect
Key Caveats:
Heart failure patients: Avoid infliximab doses >5 mg/kg in moderate-to-severe heart failure (NYHA class III/IV) due to documented increased mortality risk 9, 2
Acute infusion reactions: Monitor during infusion for cardiovascular events (MI, arrhythmias, stroke) that can occur within 24 hours 2
Anti-drug antibodies: Development of anti-infliximab antibodies may reduce efficacy and potentially negate vascular protective effects 8
Individual risk assessment: In patients with established atherosclerotic disease, weigh the cardiovascular benefits of controlling systemic inflammation against theoretical concerns, recognizing that untreated inflammation likely poses greater vascular risk
In summary, Remicade does not cause arterial thrombosis or increase atherosclerosis in the general population and is specifically indicated for treating arterial involvement in certain vasculitides. The primary cardiovascular concern is worsening heart failure in susceptible patients, not arterial thrombotic disease.